Ra Capital Management, L.P. Buys 31,000 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 31,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were purchased at an average price of $8.88 per share, with a total value of $275,280.00. Following the acquisition, the director directly owned 16,794,043 shares in the company, valued at approximately $149,131,101.84. The trade was a 0.18% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.98 per share, for a total transaction of $16,846.48.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Trading Up 1.3%

Shares of ARTV opened at $9.70 on Wednesday. The firm has a market cap of $239.78 million, a P/E ratio of -2.74 and a beta of 2.38. Artiva Biotherapeutics, Inc. has a 12-month low of $1.50 and a 12-month high of $14.53. The company’s 50-day moving average price is $9.29 and its 200 day moving average price is $6.67.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. HC Wainwright lifted their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Wedbush upped their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Needham & Company LLC restated a “buy” rating and set a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE grew its stake in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Artiva Biotherapeutics during the first quarter worth $131,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Artiva Biotherapeutics during the fourth quarter worth $91,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Artiva Biotherapeutics in the first quarter valued at $139,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.